Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
K757
- Development stage
- Phase 2
- Lead developer
- Kallyope
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
K757 is an investigational oral small-molecule GPR40 agonist developed by Kallyope, Inc. It belongs to a class of nutrient receptor agonists designed to target the gut-brain axis. By stimulating gut enteroendocrine cells, K757 triggers the secretion of satiety hormones such as glucagon-like peptide-1 (GLP-1), peptide YY (PYY), and cholecystokinin (CCK), mimicking the hormonal effects of bariatric surgery to suppress appetite. Developed using the Klarity™ computational biology platform, K757 is being evaluated for the treatment of obesity and type 2 diabetes, both as a monotherapy and in combination with K-833, a GPR119 agonist.
02
Targets
FFAR1 (Free fatty acid receptor 1)
Beyond the preview
Go deeper on K757.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on K757.